Mehmet Ufuk ABACIOĞLU Neolife Medical Center, İstanbul, Turkey
|
|
- Annabel Ford
- 5 years ago
- Views:
Transcription
1 Updated Oncology 2015: State of the Art News & Challenging Topics CURRENT STATUS OF STEREOTACTIC RADIOSURGERY IN BRAIN METASTASES Mehmet Ufuk ABACIOĞLU Neolife Medical Center, İstanbul, Turkey Bucharest, 16 June 2015
2 Conflict of Interest Disclosure Receipt of honoraria: Varian, Brainlab
3 Stereotactic Radiosurgery (SRS) Stereotactic Ablative Radiotherapy (SABR) = High dose, precisely targeted radiation treatment given in single or few fractions
4 BRAIN METASTASES Increasing due to better diagnosis, longer survival Each year new patients with BM in US Incidence and mortality more than any specific cancer!!! DS- GPA study*, 4259 pts, 11 Institutes 1 met= 40% 2-3 mets= 33% >3 mets= 27%
5 Steroids +/- WBRT n=48 Prednisone Prednisone + WBRT 40 Gy Clinical Remission 63% 61% Remission Duration 5 weeks 11 weeks Median Survival 10 weeks 14 weeks Horton J, Am J Roentgenol Radium Ther Nucl Med. 1971
6 QUARTZ trial BSC vs BSC+WBRT in NSCLC brain mets n=538 (not suitable for resection or SRS) KPS<70: 38% OS BSC: 57 days BSC+WBRT: 65 days Mulvenna PM, ASCO 2015
7 Diameter 20 mm mm mm MTD 24 Gy 18 Gy 15 Gy
8 WBRT +/- RS boost RTOG 9508, 1-3 mets, RPA I- II, 333 patients WBRT 3750 cgy/15 fx +/- RS Cause of death NS(>2/3 systemic) Single met OS 4.9 m 6.5 m, 2-3 mets NS Local control 71% vs 82% (p=0.01) Stable or increased 6 months %27 vs %43 (p=0.03) Decrease in the steroid use Andrews, Lancet 2004
9 WBRT +/- RS boost 2-4 mets Pittsburg, 27 patients, early stopped due to interim analysis (60% of planned accrual) Local 100% 8% Better brain control with WBRT+SRS Overall Survival 7.5 m vs 11 m (NS) Kondziolka, IJROBP 1999
10 RS Alone More common in routine practice Local control is high, morbidity low Overall survival is not different w/out addition of WBRT WBRT decreases the incidence of primary and new brain recurrences
11 RS +/- WBRT JROSG 99-1, 1-4 mets, <3 cm, 132 patients %85 RPA II, %50 active EC disease Intracranial 76% 47% (p<.001) Salvage tx n=29 n=10 (p<.001) OS similar(8 m vs 7.5 m) Neurological death 19% vs 23% (p=.64) Aoyama, JAMA 2006
12 n=160 n=199
13 Sx or RS +/- WBRT Obs WBRT PS 2 mos 10 m 9.5 m mos 10.9 m 10.7 m Kocher, JCO 2011
14 Sx or RS +/- WBRT Intracranial 2y Sx (%) Sx+WBRT (%) SRS (%) SRS+WBRT (%) Initial sites New sites Kocher, JCO 2011
15 EORTC QOL QLQ C30 + Brain Cancer Module Overall, patients in the observation only arm reported better HRQOL scores than did patients who received WBRT. The differences were statistically significant and clinically relevant mostly during the early follow- up period (for global health status at 9 months, physical functioning at 8 weeks, cognitive functioning at 12 months, and fatigue at 8 weeks). Soffietti, JCO 2013
16 MDACC, n=58, 1-3 met, RPA 1-2 Neurocognitive function with HVLT
17 Aoyama et al (JROSG) 2006: 132 pts Chang et al (MDACC) 2009: 58 pts Kocher et al (EORTC) 2011: 199 pts Overall 389 pts / 364 eligible for metaanalysis Sahgal, IJROBP2015
18 Median SRS SRS+WBRT Time to local recurrence Time to distant failure 6.6m 7.4m 4.7m 6.5m Overall survival 10m 8.2m
19 <50 yo patients <50 yo patients had a similar local and distant failure with SRS alone mos in pts 50: 13.6m vs 8.2m mos in pts >50: 10.1m vs 8.6m
20
21 Comment n of <50yo patients is only 68 Post hoc analysis Lung cancer is more frequent in the SRS+WBRT group, while RCC is more in the SRS group Better OS with SRS compared to SRS+WBRT may be overvalued We need to conduct disease specific prospective studies
22 Brown P, ASCO 2015
23 Brown P, ASCO 2015
24 Brown P, ASCO 2015
25 Brown P, ASCO 2015
26
27 Largest tumour <10 cc and <3 cm in longest diameter Total cumulative volume 15 cc KPS pts, 23 centers in Japan Yamamoto, Lancet Oncol 2014
28 Any adverse event 7% vs 9% vs 9% Yamamoto, Lancet Oncol 2014
29 SRS for multiple mets Karlsson, Neurosurgery centers 1921 patients Chang, J Neurosurg patients >15
30 NAGKC SRS for 5 Brain Mets A Randomized Controlled Study Of Neurocognitive Outcomes In Patients With Five Or More Brain Metastases Treated With SRS or WBRT 10 cc largest tumor volume 15 cc total tumor volume Planned accrual n: 120 Primary endpoint: NCF at 6 months
31
32 Local control according to diameter/dose Goodman, IJROBP 2001
33 Large mets Surgical resection is the standard treatment Prompt response with decompression Increased QOL, better neurological outcome Definite pathologic dx Not feasible for all patients Fractionated SRS may be a viable option Increase the local control Deecrease the toxicity of single fx SRS
34 frame frameless
35 , 135 pts with 1-3 mets (w/o previous WBRT) < 2cm: 3x12 Gy (44%) 2cm: 3x9 Gy (56%) 1-3 mm PTV margin mgtv 10.1 cc ( ) mptv 16.4 cc ( cc)
36 mos: 14.8m LC 1y: 88% LC 2y: 72% Radionecrosis 12/171 mets (7%) 9% at 1y, Poor prognosis for LC on MVA: Melanoma histology
37 , 11 studies reporting LC rates, fixed dose & size of mets
38 SRS series Local Control 6m 12m 21Gy >80% >80% 18Gy >80% >60% 15Gy >80% <50%
39 fsrt series Local Control 6m 12m fsrt >90% >70%
40 180 patients n % Age Neolife Medical Center, TrueBeam STx with Novalis using ExacTrac and Brainlab 6- D couch median 59 (29-87) Gender (F/M) 68/112 38% / 62% Number of mets median % % % > % Median Range Largest diameter 20 mm (4-60 mm) Vol of largest met 3.2 cc ( cc) Total volume 4.4 cc ( cc) ESTRO Forum 2015 PO- 0802
41 Patient characteristics n % Primary tumor Lung % Breast 29 16% GIS 12 7% Renal, Melanoma 12 7% Others 9 5% Primary controlled % Distant metastasis present % Newly diagnosed/recurrent 117/63 65%/35% Previous WBRT 63 35%
42 Diameter and Fractionation >30 mm mm mm SRS FSRT </=10 mm Fractions Doses % 1 fx (n=56) median 18 Gy (14-20 Gy) 31 3 fx (n=51) median 24 Gy (18-27 Gy) 28 4 fx (n=2) (20-24 Gy) 1 5 fx (n=71) median 30 Gy ( Gy) 40
43 OS and diameter mos= 12 m (New 13m, Rec 8m) 20mm= 17m 21-30mm= 12m 30 mm= 7m
44 Local Control and diameter Local control in >3 cm mets New Rec 6m (%) 1y (%) 10 mm mm mm mm 97 69
45 54yo, NSCLC, Metastasectomy 7 m ago 60 mm, 59 cc, 5x6 Gy Before 3 months 9 months
46 SRS to Surgical Cavity Patients with mass effect may need resection for decompression
47 Addition of Sx to WBRT Patchell #1, Kentucky, 1990, n=48 OS: 15w vs 40 w, LR: 52% vs 20% Noordijk, Leiden, 1994, n=63 OS 6m vs 10 m Mintz, Canada, 1996, n=84 (lower KPS pts) OS 6m vs 6m
48 Addition of WBRT to Sx Patchell #2, 1998, n=95 LR 46% vs 10% (p<0.001) Distant brain progression 37% vs 14% (p<0.01) Neurological death 44% vs 14% (p=0.003) Overall survival (43w vs 48w) and functional independence NS
49 After surgery, at 2 years, WBRT reduced the probability of relapse at initial sites from 59% to 27% (p<0.001)
50 SRS as an alternative to WBRT after surgery in order to improve local control eliminate/delay the toxicity of WBRT
51 Preop Postop SRS Plan 3 months
52 >1000 pts LC=70-100% Amsbaugh MJ, Austin J Med Oncol. 2014
53 SRS for Surgical Cavity Small cavity = Single fraction Large cavity = Fractionated
54 Fractionation in larger cavities n=101, >3cm cavities 3x9 Gy, 2 mm margin Local control 93%@1y 84%@2y Similar in radiosensitive and resistant histologies Radionecrosis 9% (symptomatic 5%) Minniti, IJROBP 2013
55 Timing of SRS Usually 2-4 weeks after Sx The greatest volume change occurs immediately after surgery (postop days 0-3) There is no need to wait for cavity shrinkage after 1 or 2 weeks Atalar, Neurosurgery 2013
56 Effect of additional margin on LC Difficulty of delineation of resection bed after Sx Study Local Control (%) 0 vs 2 mm Toxicity (%) 0 vs 2 mm Nataf, France, 2008, n=93 72 vs 69 (NS) 7 vs 20 (p=0.02) Choi, Stanford, 2012, n= vs 97 (p=0.042) 8 vs 3 (NS)
57 Neoadjuvant SRS Clearer delineation of the target Theoretically reduces the risk of intraoperative spread Possible additional mass effect which may complicate the resection n=47, median 14 Gy ( Gy) Median 1 day (0-17d) between SRS and Sx LC@1y 86% Asher, IJROBP 2014
58 Prognostic factors for LC Superficial with dural involvement and >3 cm higher local recurrence Brennan, IJROBP 2014
59 Prognostic factors for LC Breast cancer = leptomeningeal spread 24 vs 9% compared to non- breast histologies (p=0.004) Atalar, IJROBP 2013
60 Complications of Postop SRS Any clinical toxicity 0-26% Surgical Radionecrosis 3% Neurocognitive function is reported to be better compared to WBRT, though prospective comparison is awaited
61 Can we replace RT with supra total resection? Yoo, J Neurosurg 2009
62 Ongoing Phase III Trials Arm 1 Arm 2 Primary endpoint MDACC Observation Cavity SRS NCCTG- NCI- NRG 1270 WBRT Cavity SRS Poland WBRT Cavity SRS Local Control Overall Survival Neurocognitive Function Failure- free Survival Neurocognitive Function
63 Conclusion- I SRS alone is an effective treatment for brain metastases (not limited with number) For tumors <2 cm, single fraction achieves high local control with low toxicity For larger mets hypofractionation may increase the local control rate with lower toxicity Histopathology, number and cumulative volume of mets may further guide for the choice of treatment
64 Conclusion- II Surgery alone has a high rate of local recurrence which requires salvage treatments Both local recurrence and the salvage treatments may impair the QOL of the patients. SRS to the cavity is an effective local RT method which increases the local control with lesser toxicity compared to WBRT
The Role of Radiation Therapy in the Treatment of Brain Metastases. Matthew Cavey, M.D.
The Role of Radiation Therapy in the Treatment of Brain Metastases Matthew Cavey, M.D. Objectives Provide information about the prospective trials that are driving the treatment of patients with brain
More informationStereotactic Radiosurgery for Brain Metastasis: Changing Treatment Paradigms. Overall Clinical Significance 8/3/13
Stereotactic Radiosurgery for Brain Metastasis: Changing Treatment Paradigms Jason Sheehan, MD, PhD Departments of Neurosurgery and Radiation Oncology University of Virginia, Charlottesville, VA USA Overall
More informationMinesh Mehta, Northwestern University. Chicago, IL
* Minesh Mehta, Northwestern University Chicago, IL Consultant: Adnexus, Bayer, Merck, Tomotherapy Stock Options: Colby, Pharmacyclics, Procertus, Stemina, Tomotherapy Board of Directors: Pharmacyclics
More informationAlleinige Radiochirurgie und alleinige Systemtherapie zwei «extreme» Entwicklungen in der Behandlung von Hirnmetastasen?
Department of Radiation Oncology Chairman: Prof. Dr. Matthias Guckenberger Alleinige Radiochirurgie und alleinige Systemtherapie zwei «extreme» Entwicklungen in der Behandlung von Hirnmetastasen? Matthias
More informationCollection of Recorded Radiotherapy Seminars
IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org The Management of Brain Metastases Dr. Luis Souhami Professor Department of Radiation Oncology University,
More informationTreatment of Brain Metastases
1 Treatment of Brain Metastases An Overview and Pending Research Questions To Answer Olav E. Yri, MD, PhD www.ntnu.no/prc European Palliative Care Research Centre (PRC) The brain metastases diagnosis Outline
More informationOptimal Management of Isolated HER2+ve Brain Metastases
Optimal Management of Isolated HER2+ve Brain Metastases Eliot Sims November 2013 Background Her2+ve patients 15% of all breast cancer Even with adjuvant trastuzumab 10-15% relapse Trastuzumab does not
More informationHong Kong Hospital Authority Convention 2018
Hong Kong Hospital Authority Convention 2018 Stereotactic Radiosurgery in Brain Metastases - Development of the New Treatment Paradigm in HA, Patients Profiles and Their Clinical Outcomes 8 May 2018 Dr
More informationRadiotherapy and Brain Metastases. Dr. K Van Beek Radiation-Oncologist BSMO annual Meeting Diegem
Radiotherapy and Brain Metastases Dr. K Van Beek Radiation-Oncologist BSMO annual Meeting Diegem 24-02-2017 Possible strategies Watchful waiting Surgery Postop RT to resection cavity or WBRT postop SRS
More informationCollection of Recorded Radiotherapy Seminars
IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org The Role of Radiosurgery in the Treatment of Gliomas Luis Souhami, MD Professor Department of Radiation
More informationSelecting the Optimal Treatment for Brain Metastases
Selecting the Optimal Treatment for Brain Metastases Clinical Practice Today CME Co-provided by Learning Objectives Upon completion, participants should be able to: Understand the benefits, limitations,
More informationARROCase Brain Metastases
ARROCase Brain Metastases Colin Hill*, Daniel M. Trifiletti*, Timothy N. Showalter*, Jason P. Sheehan Radiation Oncology* and Neurosurgery University of Virginia Charlottesville, VA Case: HPI 64 year old
More informationTreating Multiple. Brain Metastases (BM)
ESTRO 36 5-9 May 2017, Vienna Austria, Accuray Symposium Treating Multiple Brain Metastases (BM) with CyberKnife System Frederic Dhermain MD PhD, Radiation Oncologist Gustave Roussy University Hospital,
More informationPlace of tumor bed radiosurgery and focal radiotherapy following resec7on of brain metastases: A new paradigm Lucyna Kepka
Place of tumor bed radiosurgery and focal radiotherapy following resec7on of brain metastases: A new paradigm Lucyna Kepka Department of Radia7on Oncology; M. Sklodowska- Curie Memorial Cancer Center and
More informationVINCENT KHOO. 8 th EIKCS Symposium: May 2013
8 th EIKCS Symposium: May 2013 VINCENT KHOO Royal Marsden NHS Foundation Trust & Institute of Cancer Research St George s Hospital & University of London Austin Health & University of Melbourne Disclosures
More informationBrain metastases and meningitis carcinomatosa: Prof. Rafal Dziadziuszko Medical University of Gdańsk, Poland
Brain metastases and meningitis carcinomatosa: a palliative situation? Prof. Rafal Dziadziuszko Medical University of Gdańsk, Poland SAMO, Lucerne, February 1-2, 2013 Treatment options for NSCLC patients
More informationTreatment of Recurrent Brain Metastases
Treatment of Recurrent Brain Metastases Penny K. Sneed, M.D. Dept. of Radiation Oncology University of California San Francisco Background Brain metastases occur in 8.5-15% of cancer pts in population-
More informationCME. Special Article. Received 27 October 2011; revised 9 December 2011; accepted 15 December Practical Radiation Oncology (2012) 2,
Practical Radiation Oncology (2012) 2, 210 225 CME www.practicalradonc.org Special Article Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): An American Society for Radiation
More informationWe have previously reported good clinical results
J Neurosurg 113:48 52, 2010 Gamma Knife surgery as sole treatment for multiple brain metastases: 2-center retrospective review of 1508 cases meeting the inclusion criteria of the JLGK0901 multi-institutional
More informationORIGINAL ARTICLE. Annals of Oncology 28: , 2017 doi: /annonc/mdx332 Published online 27 June 2017
Annals of Oncology 28: 2588 2594, 217 doi:1.193/annonc/mdx332 Published online 27 June 217 ORIGINAL ARTICLE Whole brain radiotherapy after stereotactic radiosurgery or surgical resection among patients
More informationA Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia
A Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia Gaurav Bahl, Karl Tennessen, Ashraf Mahmoud-Ahmed, Dorianne Rheaume, Ian Fleetwood,
More informationTania Kaprealian, M.D. Assistant Professor UCLA Department of Radiation Oncology August 22, 2015
Tania Kaprealian, M.D. Assistant Professor UCLA Department of Radiation Oncology August 22, 2015 Most common brain tumor, affecting 8.5-15% of cancer patients. Treatment options: Whole brain radiation
More informationProtocolos de consenso: MTS Cerebrales Resumen ASTRO. Javier Aristu y Germán Valtueña Servicio Oncología Rad. Depart.
Protocolos de consenso: MTS Cerebrales Resumen ASTRO Javier Aristu y Germán Valtueña Servicio Oncología Rad. Depart. ASTRO 2013 Brain met SRS Abstracts 97. Comparative Effectiveness of SRS versus WBRT
More informationMetastasi cerebrali La Radioterapia: tecnica, frazionamento, radiosensibilizzanti
Metastasi cerebrali La Radioterapia: tecnica, frazionamento, radiosensibilizzanti Brain Metastases Radiation Therapy of multiple brain metastases Is treatment appropriate? - Survival - QoL Brain Metastases
More informationSan Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy
San Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy Kathleen C. Horst, M.D. Assistant Professor Department of Radiation Oncology Stanford University The Optimal SEquencing of Adjuvant Chemotherapy
More informationIs it cost-effective to treat brain metastasis with advanced technology?
Is it cost-effective to treat brain metastasis with advanced technology? Cost-effectiveness analysis of whole brain RT, stereotactic radiosurgery and craniotomy in HA setting Lam, Tai-Chung, Choi CW Horace,
More informationPalliative radiotherapy in lung cancer
New concepts and insights regarding the role of radiation therapy in metastatic disease Umberto Ricardi University of Turin Department of Oncology Radiation Oncology Palliative radiotherapy in lung cancer
More informationOutline. WBRT field. Brain Metastases. Whole Brain RT Prophylactic WBRT Stereotactic radiosurgery (SRS) 1 fraction Stereotactic frame
Radiation Therapy for Advanced NSC Lung Ca Alexander Gottschalk, M.D., Ph.D. Associate Professor Director of CyberKnife Radiosurgery Department of Radiation Oncology University of California San Francisco
More informationManagement of single brain metastasis: a practice guideline
PRACTICE GUIDELINE SERIES Management of single brain metastasis: a practice guideline A. Mintz MD,* J. Perry MD, K. Spithoff BHSc, A. Chambers MA, and N. Laperriere MD on behalf of the Neuro-oncology Disease
More informationOligometastatic Disease
Oligometastatic Disease Fact or Fantasy? Jennifer R Bellon MD, FASTRO Dana-Farber Cancer Institute Harvard Medical School Alexander V Louie MD PhD, FRCPC London Health Sciences Center Western University
More informationTreating Brain Metastases in the Changing World of Oncology: Matthew Ewend, MD Kay and Van Weatherspoon Professor Chair, Department of Neurosurgery
Treating Brain Metastases in the Changing World of Oncology: Matthew Ewend, MD Kay and Van Weatherspoon Professor Chair, Department of Neurosurgery Disclosures Consultant: None Stock Holdings: None Paid
More informationWhere are we with radiotherapy for biliary tract cancers?
Where are we with radiotherapy for biliary tract cancers? Professor Maria A. Hawkins Associate Professor in Clinical Oncology MRC Group Leader/Honorary Consultant Clinical Oncologist CRUK MRC Oxford Institute
More informationTherapy of Non-Operable early stage NSCLC
SBRT Stage I NSCLC Therapy of Non-Operable early stage NSCLC Dr. Adnan Al-Hebshi MD, FRCR(UK), FRCP(C), ABR King Faisal Specialist Hospital & Research Centre This is our territory Early Stages NSCLC Surgical
More informationBrain metastases: changing visions
Brain metastases: changing visions Roberto Spiegelmann, MD Baiona, 2014 Head, Stereotactic Radiosurgery Unit Dept of Neurosurgery, Chaim Sheba Medical Center Tel Hashomer, Israel The best current estimate
More informationRESEARCH HUMAN CLINICAL STUDIES
TOPIC RESEARCH HUMAN CLINICAL STUDIES RESEARCH HUMAN CLINICAL STUDIES Radiosurgery to the Surgical Cavity as Adjuvant Therapy for Resected Brain Metastasis Jared R. Robbins, MD* Samuel Ryu, MD* Steven
More informationEvidence Based Medicine for Gamma Knife Radiosurgery. Metastatic Disease GAMMA KNIFE SURGERY
GAMMA KNIFE SURGERY Metastatic Disease Evidence Based Medicine for Gamma Knife Radiosurgery Photos courtesy of Jean Régis, Timone University Hospital, Marseille, France Brain Metastases The first report
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM BRAIN METASTASES CNS Site Group Brain Metastases Author: Dr. Norm Laperriere Date: February 20, 2018 1. INTRODUCTION
More informationRadiotherapy for Brain Metastases
Radiotherapy for Brain Metastases Robert B. Den, MD a, David W. Andrews, MD b, * KEYWORDS Brain metastases Treatment approaches SRS WBRT The optimal treatment of brain metastases remains controversial.
More informationSociety for Immunotherapy of Cancer (SITC) Immunotherapy for the Treatment of Brain Metastases
Society for Immunotherapy of Cancer (SITC) Immunotherapy for the Treatment of Brain Metastases Geoffrey T. Gibney, MD Georgetown-Lombardi Comprehensive Cancer Center Medstar-Georgetown University Hospital
More informationSergio Bracarda MD. Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy
Sergio Bracarda MD Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy Ninth European International Kidney Cancer Symposium Dublin 25-26
More informationWHAT S HOT IN MELANOMA CNS METASTASES?
WHAT S HOT IN MELANOMA CNS METASTASES? GIUSEPPE MINNITI, MD, PHD Radiation Unit, UPMC, Hillman Cancer Center, San Pietro Hospital, Rome, and IRCCS Neuromed, Pozzilli (IS), Italy Marseille, September 21-22,
More informationBrain mets under I.O.
Brain mets under I.O. Bernard Escudier Gustave Roussy, Villejuif, France Disclosure Honorarium received from BMS, Novartis, Pfizer, Bayer, Roche, Exelixis, Ipsen, Eisai, Calithera Travel Grant from BMS,
More informationInnova&ve Trial Concepts for Brain Metastases. Minesh P Mehta, MD, FASTRO Professor, University of Maryland
Innova&ve Trial Concepts for Brain Metastases Minesh P Mehta, MD, FASTRO Professor, University of Maryland Historic Trial Design A common theme has been to design an all inclusive trial that includes Most
More informationES-SCLC Joint Case Conference. Anthony Paravati Adam Yock
ES-SCLC Joint Case Conference Anthony Paravati Adam Yock Case 57 yo woman with 35 pack year smoking history presented with persistent cough and rash Chest x-ray showed a large left upper lobe/left hilar
More informationCost-effectiveness of stereotactic radiosurgery versus whole brain radiation therapy for up to 10 brain metastases
Cost-effectiveness of stereotactic radiosurgery versus whole brain radiation therapy for up to 10 brain metastases Nataniel H. Lester-Coll, MD, Arie P. Dosoretz, MD, MBA, Maxwell S. Laurans, MD, Veronica
More informationAdvances in Radiation Therapy
Advances in Radiation Therapy 2017 Recent Advances in Oncology Michelle Alonso-Basanta, MD PhD Helene Blum Assistant Professor Associate Chief of Clinical Operations Director of Quality Assurance Chief,
More informationSurgery for recurrent brain metastases
Surgery for recurrent brain metastases Pr Philippe METELLUS Neurosurgeon, Clairval Hospital Center, Marseille 8th Annual Brain Metastases Research and Emerging Therapy Conference September 21st, 2018 Conflict
More informationRadiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy. Julia White MD Professor, Radiation Oncology
Radiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy Julia White MD Professor, Radiation Oncology Agenda Efficacy of radiotherapy in the management of breast cancer in the Adjuvant
More informationManagement of Brain Metastases Sanjiv S. Agarwala, MD
Management of Brain Metastases Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA, USA Incidence (US):
More informationLocal control after fractionated stereotactic radiation therapy for brain metastases
J Neurooncol (2014) 120:339 346 DOI 10.1007/s11060-014-1556-5 CLINICAL STUDY Local control after fractionated stereotactic radiation therapy for brain metastases Selvan Rajakesari Nils D. Arvold Rachel
More informationSBRT in early stage NSCLC
SBRT in early stage NSCLC Optimal technique and tumor dose Frank Zimmermann Clinic of Radiotherapy and Radiation Oncology University Hospital Basel Petersgraben 4 CH 4031 Basel radioonkologiebasel.ch Techniques
More informationJefferson Digital Commons. Thomas Jefferson University. Mark E Linskey Department of Neurosurgery, University of California-Irvine Medical Center
Thomas Jefferson University Jefferson Digital Commons Department of Neurosurgery Faculty Papers Department of Neurosurgery 1-1-2010 The role of stereotactic radiosurgery in the management of patients with
More information3.3 SRS / neurochirurgische resectie met of zonder WBRT I Study ID II Method III Patient
1. Andrews DW et al, Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial,
More informationKEY WORDS: Stereotactic radiosurgery, Brain metastases, Guideline, Review
REVIEW Samuel T. Chao, MD Antonio De Salles, MD Motohiro Hayashi, MD Marc Levivier, MD, PhD Lijun Ma, PhD # Roberto Martinez, MD Ian Paddick, MSc Jean Régis, MD Samuel Ryu, MD Ben J. Slotman, MD Arjun
More informationGamma Knife Radiosurgery A tool for treating intracranial conditions. CNSA Annual Congress 2016 Radiation Oncology Pre-congress Workshop
Gamma Knife Radiosurgery A tool for treating intracranial conditions CNSA Annual Congress 2016 Radiation Oncology Pre-congress Workshop ANGELA McBEAN Gamma Knife CNC State-wide Care Coordinator Gamma Knife
More informationHow can we Personalize RT as part of Breast-Conserving Therapy?
How can we Personalize RT as part of Breast-Conserving Therapy? Jay R. Harris Dana-Farber Cancer Institute (DFCI) Brigham and Women s Hospital (BWH) Harvard Medical School Disclosures I have no COI disclosures
More informationMarcello Marchetti. Radioterapia Stereotassica Ipofrazionata metastasi cerebrali
Radioterapia Stereotassica Ipofrazionata metastasi cerebrali Marcello Marchetti Radiotherapy Unit, Fondazione IRCCS Istituto Neurologico C Besta, Milano, Italy Radiosurgery Evidences - Single dose stereotactic
More informationSurvival and Intracranial Control of Patients With 5 or More Brain Metastases Treated With Gamma Knife Stereotactic Radiosurgery
ORIGINAL ARTICLE Survival and Intracranial Control of Patients With 5 or More Brain Metastases Treated With Gamma Knife Stereotactic Radiosurgery Ann C. Raldow, BS,* Veronica L. Chiang, MD,w Jonathan P.
More informationCONGRESS OF NEUROLOGICAL SURGEONS SYSTEMATIC REVIEW AND
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 CONGRESS OF NEUROLOGICAL SURGEONS SYSTEMATIC REVIEW AND EVIDENCE-BASED GUIDELINES ON THE USE OF STEREOTACTIC RADIOSURGERY IN THE
More informationPrognostic indices in stereotactic radiotherapy of brain metastases of non-small cell lung cancer
Kaul et al. Radiation Oncology (2015) 10:244 DOI 10.1186/s13014-015-0550-1 RESEARCH Open Access Prognostic indices in stereotactic radiotherapy of brain metastases of non-small cell lung cancer David Kaul
More informationHigh Risk Localized Prostate Cancer Treatment Should Start with RT
High Risk Localized Prostate Cancer Treatment Should Start with RT Jason A. Efstathiou, M.D., D.Phil. Assistant Professor of Radiation Oncology Massachusetts General Hospital Harvard Medical School 10
More informationCombined treatment of Brain metastases: Radiosurgery and Targeted therapy
Combined treatment of Brain metastases: Radiosurgery and Targeted therapy Stephanie Kroeze, MD PhD OVERVIEW Introduction brain metastases Targeted therapy as monotherapy Efficacy of SRS combined with Targeted
More informationRadiation Therapy for Liver Malignancies
Outline Radiation Therapy for Liver Malignancies Albert J. Chang, M.D., Ph.D. Department of Radiation Oncology, UCSF March 23, 2014 Rationale for developing liver directed therapies Liver directed therapies
More informationTHE ROLE OF RADIATION THERAPY IN MANAGEMENT OF PANCREATIC ADENOCARCINOMA. TIMUR MITIN, MD, PhD
THE ROLE OF RADIATION THERAPY IN MANAGEMENT OF PANCREATIC ADENOCARCINOMA TIMUR MITIN, MD, PhD RESECTABLE DISEASE MANAGEMENT: RESECTABLE DISEASE Resection offers the only possibility of long term survival
More informationStereotactic radiotherapy
Stereotactic radiotherapy Influence of patient positioning and fixation on treatment planning - clinical results Frank Zimmermann Institut für Radioonkologie Universitätsspital Basel Petersgraben 4 CH
More informationAn update on radiation therapy for brain metastases
Review Article Page 1 of 8 An update on radiation therapy for brain metastases Tai-Chung Lam 1, Arjun Sahgal 2, Simon S. Lo 3, Eric L. Chang 4 1 Department of Clinical Oncology, Li Ka Shing Faculty of
More informationOverview: Immunotherapy in CNS Metastases
Overview: Immunotherapy in CNS Metastases Manmeet Ahluwalia, MD, FACP Miller Family Endowed Chair in Neuro-Oncology Director Brain Metastasis Research Program Cleveland Clinic Disclosures Consultant- Monteris
More informationRadiation and DCIS. The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging
Radiation and DCIS The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging Einsley-Marie Janowski, MD, PhD Assistant Professor Department of Radiation Oncology
More informationPalliative radiotherapy near the end of life for brain metastases from lung cancer: a populationbased
Palliative radiotherapy near the end of life for brain metastases from lung cancer: a populationbased analysis Roel Schlijper Fellow Radiation Oncology BC Cancer, Prince George Disclosures No conflicts
More informationWhat s New in Radiotherapy For STS of The Extremity? Kaled M. Alektiar, MD, FASTRO Dept of Rad Onc Memorial Sloan Kettering Cancer Center
What s New in Radiotherapy For STS of The Extremity? Kaled M. Alektiar, MD, FASTRO Dept of Rad Onc Memorial Sloan Kettering Cancer Center Topics Predictive tools for risk assessment Reassessment of dose/volume
More informationCNS Metastases in Breast Cancer
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer CNS Metastases in Breast Cancer CNS Metastases in Breast Cancer Version 2006: Maass / Junkermann Version 2007 2009: Bischoff
More informationCase Conference: SBRT for spinal metastases D A N I E L S I M P S O N M D 3 / 2 7 / 1 2
Case Conference: SBRT for spinal metastases D A N I E L S I M P S O N M D 3 / 2 7 / 1 2 Case 79 yo M with hx of T3N0 colon cancer diagnosed in 2008 metastatic liver disease s/p liver segmentectomy 2009
More informationClinical Aspects of SBRT in Abdominal Regions Brian D. Kavanagh, MD, MPH University of Colorado Department of Radiation Oncology
Clinical Aspects of SBRT in Abdominal Regions Brian D. Kavanagh, MD, MPH University of Colorado Department of Radiation Oncology Abdominal SBRT: Clinical Aspects Rationales for liver and pancreas SBRT
More informationMulticenter analysis of stereotactic radiotherapy of the resection cavity in patients with brain metastases
Cancer Medicine ORIGINAL RESEARCH Open Access Multicenter analysis of stereotactic radiotherapy of the resection cavity in patients with brain metastases Stephanie E. Combs 1,2,3, Angelika Bilger 4,5,
More informationRadiotherapy for rectal cancer. Karin Haustermans Department of Radiation Oncology
Radiotherapy for rectal cancer Karin Haustermans Department of Radiation Oncology O U T L I N E RT with TME surgery? Neoadjuvant or adjuvant RT? 5 x 5 Gy or long-course CRT? RT with new drugs? Selection
More informationRole of Prophylactic Cranial Irradiation in Small Cell Lung Cancer
Role of Prophylactic Cranial Irradiation in Small Cell Lung Cancer Kazi S. Manir MD,DNB,ECMO,PDCR Clinical Tutor Department of Radiotherapy R. G. Kar Medical College and Hospital, Kolkata SCLC 15% of lung
More informationSBRT in Pancreas Cancer Role of The Radiosurgery Society
SBRT in Pancreas Cancer Role of The Radiosurgery Society Anand Mahadevan MD FRCS FRCR Chairman Division of Radiation Oncology Geisinger Health System, Danville, PA, USA. Past President and Chairman: The
More informationUpdate on management of metastatic brain disease. Peter Hoskin Mount Vernon Cancer Centre Northwood UK
Update on management of metastatic brain disease Peter Hoskin Mount Vernon Cancer Centre Northwood UK Incidence 15-30% of patients with solid tumours will develop brain metastases Most common primary sites
More informationProphylactic Cranial Irradiation and Thoracic Radiotherapy in Extensive Stage Small-Cell Lung Cancer
Prophylactic Cranial Irradiation and Thoracic Radiotherapy in Extensive Stage Small-Cell Lung Cancer Dr Neil Bayman Consultant Clinical Oncology ESMO-Christie Preceptorship Programme in Lung Cancer, March
More informationReirradiazione. La radioterapia stereotassica ablativa: torace. Pierluigi Bonomo Firenze
Reirradiazione La radioterapia stereotassica ablativa: torace Pierluigi Bonomo Firenze Background Stage III NSCLC isolated locoregional recurrence in 25% of pts mostly unresectable; low RR with 2 nd line
More informationPotential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases
clinical article J Neurosurg 123:1261 1267, 2015 Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases *Jessica M. Frakes, MD,
More informationThe Evolution of SBRT and Hypofractionation in Thoracic Radiation Oncology
The Evolution of SBRT and Hypofractionation in Thoracic Radiation Oncology (specifically, lung cancer) 2/10/18 Jeffrey Kittel, MD Radiation Oncology, Aurora St. Luke s Medical Center Outline The history
More informationAdditional radiation boost to whole brain radiation therapy may improve the survival of patients with brain metastases in small cell lung cancer
Sun et al. Radiation Oncology (2018) 13:250 https://doi.org/10.1186/s13014-018-1198-4 RESEARCH Open Access Additional radiation boost to whole brain radiation therapy may improve the survival of patients
More informationCURRENT ADVANCES IN RADIATION THERAPY
CURRENT ADVANCES IN RADIATION THERAPY ESMO Summit Africa 2018 Suresh Senan Radiation oncologist, VU University medical center Amsterdam, The Netherlands CONFLICT OF INTEREST DISCLOSURE Research grants:
More informationRadioterapia no Tratamento dos Gliomas de Baixo Grau
Radioterapia no Tratamento dos Gliomas de Baixo Grau Dr. Luis Souhami University Montreal - Canada Low Grade Gliomas Relatively rare Heterogeneous, slow growing tumors WHO Classification Grade I Pilocytic
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 4,100 116,000 120M Open access books available International authors and editors Downloads Our
More informationBr a i n metastases occur in 20 40% of all patients. The results of resection after stereotactic radiosurgery for brain metastases.
J Neurosurg 111:825 831, 2009 The results of resection after stereotactic radiosurgery for brain metastases Clinical article Hi d e y u k i Ka n o, M.D., Ph.D., 1,3 Do u g l a s Ko n d z i o l k a, M.D.,
More informationNRG Publications Committee. Chair: Deborah Watkins Bruner, PhD Co-chairs: Elizabeth Gore, MD Thomas Julian, MD Krish Tewari, MD
NRG Publications Committee Chair: Deborah Watkins Bruner, PhD Co-chairs: Elizabeth Gore, MD Thomas Julian, MD Krish Tewari, MD NRG Abstract and Manuscript Submissions 161 Manuscripts 105 Publications in
More informationUpdate on Limited Small Cell Lung Cancer. Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver
Update on Limited Small Cell Lung Cancer Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver Objectives - Limited Radiation Dose Radiation Timing Radiation Volume PCI Neurotoxicity
More information4D Radiotherapy in early ca Lung. Prof. Manoj Gupta Dept of Radiotherapy & oncology I.G.Medical College Shimla
4D Radiotherapy in early ca Lung Prof. Manoj Gupta Dept of Radiotherapy & oncology I.G.Medical College Shimla Presentation focus on ---- Limitation of Conventional RT Why Interest in early lung cancer
More informationTargeted/Immunotherapy & Molecular Profiling State-of-the-art in Cancer Care
Targeted/Immunotherapy & Molecular Profiling State-of-the-art in Cancer Care Manmeet Ahluwalia, MD, FACP Miller Family Endowed Chair in Neuro-Oncology Director Brain Metastasis Research Program Cleveland
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,800 116,000 120M Open access books available International authors and editors Downloads Our
More informationCarcinoma del retto: Highlights
Carcinoma del retto: Highlights Stefano Cordio Struttura Complessa di Oncologia Medica ARNAS Garibaldi Catania Roma 17 Febbraio 2018 Disclosures Advisory Committee, research funding and speakers bureau
More informationSUCCESSFUL TREATMENT OF METASTATIC BRAIN TUMOR BY CYBERKNIFE: A CASE REPORT
SUCCESSFUL TREATMENT OF METASTATIC BRAIN TUMOR BY CYBERKNIFE: A CASE REPORT Cheng-Ta Hsieh, 1 Cheng-Fu Chang, 1 Ming-Ying Liu, 1 Li-Ping Chang, 2 Dueng-Yuan Hueng, 3 Steven D. Chang, 4 and Da-Tong Ju 1
More informationRadiotherapy symptoms control in bone mets. Francesco Cellini GemelliART. Ernesto Maranzano,MD. Session 5: Symptoms management
Session 5: Symptoms management Radiotherapy symptoms control in bone mets Francesco Cellini GemelliART Ernesto Maranzano,MD Director of Oncology Department Chief of Radiation Oncology Centre S. Maria Hospital
More informationQuality of life in brain metastases radiation trials: a literature review
RADIATION ONCOLOGY Quality of life in brain metastases radiation trials: a literature review J. Wong,* A. Hird,* A. Kirou Mauro,* J. Napolskikh BSc,* and E. Chow MBBS* ABSTRACT Background An estimated
More informationHypofractionated radiation therapy for glioblastoma
Hypofractionated radiation therapy for glioblastoma Luis Souhami, MD, FASTRO Professor McGill University Department of Oncology, Division of Radiation Oncology Montreal Canada McGill University Health
More informationLocally advanced disease & challenges in management
Gynecologic Cancer InterGroup Cervix Cancer Research Network Cervix Cancer Education Symposium, February 2018 Locally advanced disease & challenges in management Carien Creutzberg Radiation Oncology, Leiden
More informationNews Briefing New Developments in Pediatric & Adult CNS Malignancies
News Briefing New Developments in Pediatric & Adult CNS Malignancies Tuesday, Sept. 24, 2013 2:45 p.m. Daphne Haas-Kogan, MD University of California, San Francisco Cost-effectiveness of Proton Therapy
More informationAdjuvant Radiotherapy for completely resected NSCLC
Adjuvant Radiotherapy for completely resected NSCLC ESMO Preceptorship on lung Cancer Manchester February 2017 Cécile Le Péchoux Radiation Oncology Department IOT Institut d Oncologie Thoracique Local
More information